|AgenDx Biosciences||/assets/241392/fullsize/agendx.jpg||true||AgenDx Biosciences, Inc.: AgenDx Biosciences is an early stage molecular diagnostics company developing a revolutionary cost-effective molecular diagnostics platform. Our novel technology allows simple molecular diagnostic lab-quality testing. With a quick sample-to-answer in minutes, our platform is positioned to transform where and how disease is detected and treated. Learn more at http://agendxbio.com. || || |
|Anfiro||/assets/242080/fullsize/anfiro.png||true||Anfiro™ is a water technology start-up addressing global freshwater scarcity. We are using our self-assembling polymers to create chlorine resistant and high permeability reverse osmosis (RO) and nanofiltration (NF) membranes that vastly outperform current membrane technology. This enables us to significantly reduce the cost of water treatment and desalination, enabling clean and affordable water for a better tomorrow.|| || |
|Cetya Therapeutics||/assets/242083/fullsize/cetya.png||true||Cetya Therapeutics, Inc. (“Cetya”) was formed in 2012 to commercialize histone deacetylase inhibitors (HDACi) based on largazole. Some of these analogs have bifunctional modifications and the potential to target specific cell types or tumors.
This is unique in the HDACi space and, together with potency and selectivity, differentiates Cetya’s compounds. Cetya holds exclusive license rights to the largazole analog intellectual property created by Dr. Robert M. Williams at Colorado State University. More than 40 largazole analogs have been synthesized, some with best-in-class profiles as HDACi. Biochemical and cell-based potency, upregulation of fetal hemoglobin expression and in-vivo anti-cancer activity have been demonstrated.
As a drug class, HDACis have been demonstrated to be effective in treating certain cancers and thought leaders in epigenetics believe that this class of compounds may have much broader application in treating hemoglobinopathies, chronic inflammation, neurological disorders, fibrotic diseases, and enhance the efficacy of antiretroviral therapy for HIV by reactivating latent pools of virus. All of these indications will be investigated as the preclinical dataset around Cetya’s analogs matures.|| || |
|EmNet||/assets/242081/fullsize/emnet.png||true||EmNet is the only company that offers an open, integrated technology platform for the smart water utility of the future. Our technology and consulting services enable comprehensive understanding, control, and dynamic optimization of water infrastructure, drastic reductions in water and wastewater overflow, and consistently improving system performance over time—all at a fraction of the cost of traditional overflow mitigation strategies.|| || |
|Emu Solutions||/assets/241366/fullsize/emu.jpg||true||EMU Solutions, Inc.: Emu Solutions is commercializing technologies to eliminate the bottleneck between memory and logic capabilities in computer systems. An increasingly common and critical issue for businesses and government, the proprietary "Enhanced Memory Utilization (EMU)" hardware and software technology frees the flow of data between processors and memory. The company was founded in 2004 by Notre Dame computer science and engineering professors Peter Kogge and Jay Brockman and California Institute of Technology researcher Ed Upchurch. The technology draws on patents licensed through the University of Notre Dame. http://www.emutechnology.com/|| || |
|F Cubed||/assets/242082/fullsize/f3.png||true||F Cubed®, LLC, (F Cubed®; F3) was founded on the objective to create a molecular diagnostic method which could take a raw sample to a full assay in less than one hour in any location.
Based in South Bend, Indiana, home of the University of Notre Dame, F3 benefits from a diverse workforce of specialists with expertise in life sciences, engineering, and entrepreneurship. We have attracted talent from across the United States with graduates from institutions such as the University of Notre Dame, Princeton University, Purdue University, the University of Texas, University of Pennsylvania, University of Pittsburgh, and the University of California.
Our rapid detection system, based on AC Dielectrophoretic technology, was developed by Dr. Hseuh-Chia Chang, the Bayer Professor of Chemical Engineering at the University of Notre Dame. F Cubed continues to benefit from affiliation with the University.
The City of South Bend has shown their commitment to the creation of high technology businesses, in general, and to F3, in particular, through the innovative leasing of production equipment for our proprietary biochips and related consumables. This includes specialized robotic and semi-automated production lines.
Individually and as a company, we aspire to change the world for the better by offering revolutionary diagnostic solutions.|| || |
|Hsiri Therapeutics||/assets/241374/fullsize/hsiri.jpg||true||Hsiri Therapeutics, LLC: Hsiri Therapeutics is a privately held pharmaceutical company focusing on antibiotics. The Company has three development programs all licensed in from the laboratories of Dr. Marvin Miller at the University of Notre Dame. All three programs are at the pre-clinical stage but Hsiri expects to have at least one ready for IND filing by the end of 2013. http://www.hsiritherapeutics.com|| || |
|ImpeDx Diagnostics||/assets/242085/fullsize/impedx.jpg||true||ImpeDx Diagnostics has secured exclusive rights to develop and market a novel system for rapidly detecting bacteria in blood culture specimens for use in clinical laboratories.
Our mission is to reduce the mortality rate of septic patients by providing rapid diagnostic products, which will allow clinicians to administer target therapeutic treatments sooner. Our technology compresses blood culture results from days to hours. Not only will rapid identification improve mortality rate, but it will also have a major impact on healthcare savings.|| || |
|Indiana Integrated Circuits||/assets/241377/fullsize/iic.jpg||true||Indiana Integrated Circuits, LLC: Indiana Integrated Circuits LLC is working to commercialize Quilt Packaging™, a technology licensed through the University of Notre Dame to streamline microchip packaging, resulting in lower costs, greater speed and higher efficiency. The patented circuitry is designed to minimize or eliminate data transfer issues by using a much more streamlined connection than has previously been available in existing technologies, thereby reducing costs of the final product as well as communications lag time between chips. http://www.indianaic.com.|| || |
|In Vivo Concepts||/assets/242084/fullsize/invivo.png||true||In Vivo Concepts is a group of preclinical imaging scientists and engineers focused on developing novel new products to enhance small animal imaging in biomedical research. Our products are designed to improve the way animals are handled and facilitate better research while also increasing the safety of technicians. We work across all preclinical imaging modalities including optical (bioluminescence, fluorescence and digital x-ray), PET/SPECT/CT, MRI, visual sonic and photo acoustic.|| || |